Related Experiment Video

Updated: Mar 27, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Dupilumab for Chronic Spontaneous Urticaria with Comorbid Type 2 Inflammatory Conditions: Case Report and Systematic

Somaia Naassan¹, Marianne Baastrup Søndergaard¹, Celeste Porsbjerg²

¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

Case Reports in Dermatology

|March 26, 2026

Abstract

Introduction:

Chronic spontaneous urticaria (CSU) is a heterogeneous, Th2-driven condition where standard therapies, including antihistamines and omalizumab, are often insufficient. Dupilumab, an IL-4Rα antagonist approved for several Th2-mediated diseases, has shown efficacy in CSU. We present a rare case of CSU coexisting with both asthma and eosinophilic gastroenteritis, successfully treated with dupilumab, highlighting the potential effectiveness and appropriateness of dupilumab in patients with multiple, simultaneous Th2-mediated comorbidities, and provide a systematic review of the literature.

Case Presentation:

A 32-year-old man with refractory CSU, asthma, and eosinophilic gastroenteritis was treated with dupilumab. The patient achieved complete remission of CSU, asthma, and eosinophilic gastroenteritis with dupilumab, with no reported side effects. A systematic literature search of PubMed and Embase identified eight studies comprising 25 CSU patients, most with coexisting atopic dermatitis or asthma. The majority achieved symptom control of urticaria as well as of the coexisting Th2 diseases, with only one report of mild side effects.

Conclusions:

Dupilumab is a suitable therapeutic option in patients with CSU and coexisting Th2-mediated conditions.

Keywords:

Asthma Case report Chronic spontaneous urticaria Dupilumab Eosinophilic gastroenteritis T-helper 2 cell-mediated diseases

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Basophil Activation Test for Allergy Diagnosis

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Hypersensitivities

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Articles linked to this work by shared authors, journal, and citation graph.

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP.

American journal of respiratory and critical care medicine·2026

Genetic architecture of cytokine autoantibodies and associated risk of common diseases.

Nature communications·2026

Assessing the Impact of Earlier Initiation of Biologics on Clinical Remission and Other Outcomes in a Global Real-Life Severe Asthma Cohort From CHRONICLE, the International Severe Asthma Registry, and the Optimum Patient Care Research Database.

Chest·2026

Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe.

ERJ open research·2026

Airway epithelial transcriptional response to daily high-dose inhaled corticosteroids in asthma.

ERJ open research·2026

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026

See all related articles